Abstract submission will open September 1, 2016
Exhibitor & Support Opportunities
Act now to identify the best strategies at TAT 2017 to get the RESULTS your company expects in this dynamic marketplace.
Registration will open September 1, 2016
Phase 1: the revolution is ongoing!
A revolution is ongoing, which has already changed and will continue to change the role of phase 1 studies in oncology drug development.
Meet global phase 1 leaders
Expand your network with global leaders in early-phase drug development at TAT 2017. Many leading phase 1 investigators and translational research scientists are confirmed speakers or session chairs.
TAT 2016 report
A brief report of TAT 2016 is online now. Over the three days of the conference, 45 oral presentations covered 23 unique new drugs or drug classes in early-phase clinical trials at the time of the conference.